Bioprocessing

The biopharmaceutical industry has seen significant advancements, particularly in the production of monoclonal antibodies (mAbs), which offer personalized therapies for a range of chronic and debilitating conditions. Despite these advancements, manufacturers face growing pressure to expedite the

The launch of the Planova FG1 by Asahi Kasei Medical marks a pivotal advancement in virus removal technology within the bioprocessing industry. This next-generation virus removal filter is designed to enhance efficiency and safety in the production of biotherapeutics, including biopharmaceuticals

Monoclonal antibodies (mAbs) have become a cornerstone of modern medicine, offering targeted therapies for a range of diseases, including various cancers, autoimmune disorders, and infectious diseases. However, developing these complex molecules is resource-intensive, requiring significant time and

The biopharmaceutical industry has witnessed significant advancements in upstream bioprocessing over the years, but downstream bioprocessing (DSP) often lagged, creating bottlenecks that hampered overall efficiency. Recent innovations, however, are transforming the DSP landscape, offering promising

The biopharmaceutical industry is on the cusp of a revolutionary transformation that promises to redefine its future trajectory. While Biopharma 4.0 brought about significant advancements in digitization and smart manufacturing, its successor, Biopharma 5.0, aims to integrate human creativity,

Bioprocessing, with its roots in the early days of microbial fermentation, now stands as a fundamental pillar in the realm of modern biotechnology. This sophisticated field merges biological and engineering principles to harness the power of living organisms in producing a vast array of valuable